Next Hurdle in Cancer Immunorapy: Overcoming Non-T-Cell-Inflamed Tumor Microenvironment

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 663-671

  Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL HETEROGENEITY; CELLULAR IMMUNITY; DRUG EFFICACY; GENOME ANALYSIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MOLECULAR PATHOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84940372582     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.011     Document Type: Review

References (69)

1. T. Boon, P.G. Coulie, and B. Van den Eynde Tumor antigens recognized by T cells Immunol Today 18 1997 267 268
2. Y. Kawakami, P.F. Robbins, R.F. Wang, and S.A. Rosenberg Identification of tumor-regression antigens in melanoma Important Adv Oncol 1996 3 21
3. T.F. Gajewski Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond Clin Diagn Lab Immunol 7 2000 141 144
4. A.C. Peterson, H. Harlin, and T.F. Gajewski Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma J Clin Oncol 21 2003 2342 2348
5. T.F. Gajewski, Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin Immune resistance orchestrated by tumor microenvironment Immunol Rev 213 2006 131 145
6. H. Harlin, Y. Meng, A.C. Peterson, and et al. Chemokine expression in melanoma metastases associated with CD8+T-cell recruitment Cancer Res 69 2009 3077 3085
7. S. Spranger, R. Bao, and T.F. Gajewski Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature 2015 May 11 http://dx.doi.org/10.1038/nature14404. [Epub ahead of print]
8. S.A. Rosenberg, and M.E. Dudley Cancer regression in patients with metastatic melanoma after transfer of autologous antitumor lymphocytes Proc Natl Acad Sci U S A 101 Suppl 2 2004 14639 14645
9. H. Harlin, T.V. Kuna, A.C. Peterson, Y. Meng, and T.F. Gajewski Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites Cancer Immunol Immunor 55 2006 1185 1197
10. R. Mortarini, A. Piris, A. Maurichi, and et al. Lack of terminally differentiated tumor-specific CD8+T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma Cancer Res 63 2003 2535 2545
11. A. Zippelius, P. Batard, V. Rubio-Godoy, and et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance Cancer Res 64 2004 2865 2873
12. H.L. Kaufman, D.W. Kim, G. DeRaffele, J. Mitcham, R.S. Coffin, and S. Kim-Schulze Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol 17 2010 718 730
13. T.F. Gajewski Failure at effector phase: immune barriers at level of melanoma tumor microenvironment Clin Cancer Res 13 2007 5256 5261
14. S. Spranger, R.M. Spaapen, Y. Zha, J. Williams, Y. Meng, T.T. Ha, and T.F. Gajewski Up-regulation of PD-L1, IDO, and T(regs) in melanoma tumor microenvironment is driven by CD8(+) T cells Sci Transl Med 5 200 2013 200ra116
15. T.F. Gajewski, Y. Meng, and H. Harlin Chemokines expressed in melanoma metastases associated with T cell infiltration J Clin Oncol ASCO Annual Meeting Proceedings Part I 25 2007 8501
16. T.F. Gajewski, Y. Zha, B. Thurner, and G. Schuler Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine J Clin Oncol 27 2009 9002
17. T.F. Gajewski, J. Louahed, and V.G. Brichard Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunorapy Cancer J 16 2010 399 403
18. R.J. Sullivan, Y. Hoshida, J. Brunet, and et al. A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response J Clin Oncol 27 2009 15S abstract 9003
19. R.R. Ji, S.D. Chasalow, L. Wang, and et al. An immune-active tumor microenvironment favors clinical response to ipilimumab Cancer Immunol Immunor 61 7 2012 1019 1331
20. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
21. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
22. P.C. Tumeh, C.L. Harview, J.H. Yearley, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
23. S. Spranger, H.K. Koblish, B. Horton, P.A. Scherle, R. Newton, and T.F. Gajewski Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within tumor microenvironment J Immunor Cancer 2 2014 3
24. T.F. Gajewski, S.R. Woo, Y. Zha, R. Spaapen, Y. Zheng, L. Corrales, and S. Spranger Cancer immunorapy strategies based on overcoming barriers within tumor microenvironment Curr Opin Immunol 25 2013 268 276
25. R.B. Holmgaard, D. Zamarin, D.H. Munn, J.D. Wolchok, and J.P. Allison Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunorapy targeting CTLA-4 J Exp Med 210 2013 1389 1402
26. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
27. G. Gibney, O. Hamid, T. Gangadhar, and et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma J Clin Oncol 32 2014 5s (suppl; abstr 3010)
28. A. Iwasaki, and R. Medzhitov Toll-like receptor control of adaptive immune responses Nat Immunol 5 2014 987 995
29. M.B. Fuertes, A.K. Kacha, J. Kline, and et al. Host type I IFN signals are required for antitumor CD8+T cell responses through CD8{alpha}+dendritic cells J Exp Med 208 10 2011 2005 2016
30. K. Hildner, B.T. Edelson, W.E. Purtha, and et al. Batf3 deficiency reveals a critical role for CD8alpha+dendritic cells in cytotoxic T cell immunity Science 322 2008 1097 1100
31. M.S. Diamond, M. Kinder, H. Matsushita, and et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors J Exp Med 208 2011 1989 2003
32. M.B. Fuertes, S.R. Woo, B. Burnett, Y.X. Fu, and T.F. Gajewski Type I interferon response and innate immune sensing of cancer Trends Immunol 34 2013 67 73
33. H. Ishikawa, and G.N. Barber STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling Nature 455 2008 674 678
34. L. Sun, J. Wu, F. Du, X. Chen, and Z.J. Chen Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates type I interferon pathway Science 339 2013 786 791
35. X. Zhang, H. Shi, J. Wu, L. Sun, C. Chen, and Z.J. Chen Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING Mol Cell 51 2013 226 235
36. J. Ahn, D. Gutman, S. Saijo, and G.N. Barber STING manifests self DNA-dependent inflammatory disease Proc Natl Acad Sci U S A 109 2012 19386 19391
37. J. Ahn, P. Ruiz, and G.N. Barber Intrinsic self-DNA triggers inflammatory disease dependent on STING J Immunol 193 2014 4634 4642
38. Y. Liu, A.A. Jesus, B. Marrero, and et al. Activated STING in a vascular and pulmonary syndrome N Engl J Med 371 2014 507 518
39. S.-R. Woo, B Fuertes Mercedes, and et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors Immunity 41 2014 830 842
40. J. Ahn, T. Xia, H. Konno, K. Konno, P. Ruiz, and G.N. Barber Inflammation-driven carcinogenesis is mediated through STING Nat Commun 5 2014 5166
41. T. Ohkuri, A. Ghosh, A. Kosaka, and et al. STING contributes to antiglioma immunity via triggering type I IFN signals in tumor microenvironment Cancer Immunol Res 2 12 2014 1199 1208
42. Q. Zhu, S.M. Man, P. Gurung, and et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing magnitude of intestinal inflammation J Immunol 193 2014 4779 4782
43. S. Ugurel, D. Schrama, G. Keller, and et al. Impact of CCR5 gene polymorphism on survival of metastatic melanoma patients receiving immunorapy Cancer Immunol Immunor 57 2008 685 691
44. L. Uccellini, V. De Giorgi, Y. Zhao, and et al. IRF5 gene polymorphisms in melanoma J Transl Med 10 2012 170
45. G. Niu, R. Heller, R. Catlett-Falcone, and et al. Gene rapy with dominant-negative Stat3 suppresses growth of murine melanoma B16 tumor in vivo Cancer Res 59 1999 5059 5063
46. L. Burdelya, M. Kujawski, G. Niu, and et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects J Immunol 174 2005 3925 3931
47. N. Iida, A. Dzutsev, C.A. Stewart, and et al. Commensal bacteria control cancer response to rapy by modulating tumor microenvironment Science 342 2013 967 970
48. B.C. Baguley, and L.M. Ching Immunomodulatory actions of xannone anticancer agents BioDrugs 8 1997 119 127
49. P.N. Lara Jr., J.Y. Douillard, K. Nakagawa, and et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer J Clin Oncol 29 2011 2965 2971
50. J. Conlon, D.L. Burdette, S. Sharma, and et al. Mouse, but not human STING, binds and signals in response to vascular disrupting agent 5,6-dimethylxannone-4-acetic acid J Immunol 190 2013 5216 5225
51. P. Gao, M. Ascano, T. Zillinger, and et al. Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA Cell 154 2013 748 762
52. L. Corrales, L.H. Glickman, S.M. McWhirter, and et al. Direct activation of STING in tumor microenvironment leads to potent and systemic tumor regression and immunity Cell Rep 11 7 2015 1018 1030
53. X. Yang, X. Zhang, M.L. Fu, and et al. Targeting tumor microenvironment with interferon-beta bridges innate and adaptive immune responses Cancer Cell 25 2014 37 48
54. R.M. Spaapen, M.Y. Leung, M.B. Fuertes, and et al. rapeutic activity of high-dose intratumoral IFN-beta requires direct effect on tumor vasculature J Immunol 193 2014 4254 4260
55. B.C. Burnette, H. Liang, Y. Lee, and et al. efficacy of radiorapy relies upon induction of type i interferon-dependent innate and adaptive immunity Cancer Res 71 2011 2488 2496
56. L. Deng, H. Liang, M. Xu, and et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors Immunity 41 2014 843 852
57. J. Wang, J.C. Lo, A. Foster, and et al. regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT J Clin Invest 108 2001 1771 1780
58. P. Yu, Y. Lee, W. Liu, and et al. Priming of naive T cells inside tumors leads to eradication of established tumors Nat Immunol 5 2004 141 149
59. P. Yu, Y. Lee, Y. Wang, and et al. Targeting primary tumor to generate CTL for effective eradication of spontaneous metastases J Immunol 179 2007 1960 1968
60. S.S. Oh, C. Moon, D.H. Kim, H. Song, S. Park, Y. Fu, and K.D. Kim Adenovirally delivered IFN-beta exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation Int J Mol Med 29 2012 1153 1157
61. J.L. Messina, D.A. Fenstermacher, S. Eschrich, and et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: Potential for patient selection for immunorapy? Sci Rep 2 2012 765
62. R.J. Buckanovich, A. Facciabene, S. Kim, and et al. Endolin B receptor mediates endolial barrier to T cell homing to tumors and disables immune rapy Nat Med 14 2008 28 36
63. G.T. Motz, and G. Coukos parallel lives of angiogenesis and immunosuppression: Cancer and or tales Nat Rev Immunol 11 2011 702 711
64. S. Singh, S.R. Ross, M. Acena, D.A. Rowley, and H. Schreiber Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells J Exp Med 175 1992 139 146
65. B. Zhang, Y. Zhang, N.A. Bowerman, and et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma Cancer Res 68 2008 1563 1571
66. G.L. Beatty, E.G. Chiorean, M.P. Fishman, and et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612-6
67. L. Deng, H. Liang, B. Burnette, and et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice J Clin Invest 124 2014 687 695
68. M.A. Postow, M.K. Callahan, C.A. Barker, and et al. Immunologic correlates of abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
69. A. Snyder, J.D. Wolchok, and T.A. Chan Genetic basis for clinical response to CTLA-4 blockade N Engl J Med 372 8 2015 783